Anti-viral therapy in Alzheimer's disease

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Alzheimer's Disease
  • Age: Between 55 Year(s) - 95 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Subjects must be between the age fo 15 to 95 years old
    2. Female subjects must be postmenopausal defined as 12 consecutive months without menstruation.
    3. Subjects who have diagnosis of probable AD by NIA clinical diagnostic criteria.
    4. Subjects must score 18 to 28 out of 30 on the Folstein Mini State
    5. Subjects must score clinical Dementia Rating (CDR) score of 1
    6. Subjects must have a family member or other individual who is in contact with the patient and consents to serve as informant during the study
    7. Subjects retains capacity to consent for him/herself or retains the capacity to identify a surrogate who will consent on his/her behalf.
    8. Subjects must test positive for serum antibodies to HSV1 or HSV2.
    9. Subjects have use of cholinesterase inhibitors and memantine, and concomitant psychotropic medications

You may not be eligible for this study if the following are true:

    1. Subjects' caregiver is unwilling or unable, in the opinion of the investigator, to comply with study instructions.
    2. Subjects who have dementia predominantly of non-Alzheimer's type, including vascular dementia, frontotemporal dementia, Lewy body dementia, substance-induced dementia.
    3. Subjects must score greater than 4 on the Modified Hachinski scale
    4. Subjects with Current clinical diagnosis of schizophrenia, schizoaffective disorder, other psychosis, bipolar disorder or current major depression by DSM-5 criteria.
    5. Subjects with active suicidal intent or plan based on clinical assessment.
    6. Subjects who have current or recent (past 6 months) alcohol or substance use disorder
    7. Subjects with history of alcohol or drug abuse within 12 months prior to the date informed consent is obtained
    8. Subjects who have current diagnosis of other major neurological disorders, including Parkinson's disease, multiple sclerosis, CNS infection, Huntington' s disease, and amyotrophic lateral sclerosis
    9. Subjects with sitting blood pressure > 160/100 mm Hg
    10. Subjects with renal failure
    11. Subjects have serum vitamin B12 levels below the normal range.
    12. Subjects with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome
    13. Use of benzodiapezines in lorazepam equivalent doses equal to or greater than 2 mg daily.
    14. Subjects consenting to lumbar puncture (40% of sample), this procedure will be conducted if there is no lower spinal malformation or other contraindication to lumbar puncture

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.